Nanomaterials 2012, 2(3), 217-250; doi:10.3390/nano2030217

Rafts, Nanoparticles and Neural Disease

1 Ross University School of Medicine, Miami Beach Community Health Center, 11645 Biscayne Boulevard, North Miami, FL 33181, USA 2 Department of Anthropology, University of Central Florida, Orlando, FL 32816, USA
* Author to whom correspondence should be addressed.
Received: 12 June 2012; in revised form: 19 July 2012 / Accepted: 20 July 2012 / Published: 6 August 2012
(This article belongs to the Special Issue Trends of Nanomaterials in Life Sciences)
PDF Full-text Download PDF Full-Text [417 KB, uploaded 6 August 2012 13:14 CEST]
Abstract: This review examines the role of membrane rafts in neural disease as a rationale for drug targeting utilizing lipid-based nanoparticles. The article begins with an overview of methodological issues involving the existence, sizes, and lifetimes of rafts, and then examines raft function in the etiologies of three major neural diseases—epilepsy, Parkinson’s disease, and Alzheimer’s disease—selected as promising candidates for raft-based therapeutics. Raft-targeting drug delivery systems involving liposomes and solid lipid nanoparticles are then examined in detail.
Keywords: rafts; nanoparticles; nanomedicine; neural disease; epilepsy; Parkinson’s disease, Alzheimer’s disease; liposomes; solid lipid nanoparticles

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Gulati, V.; Wallace, R. Rafts, Nanoparticles and Neural Disease. Nanomaterials 2012, 2, 217-250.

AMA Style

Gulati V, Wallace R. Rafts, Nanoparticles and Neural Disease. Nanomaterials. 2012; 2(3):217-250.

Chicago/Turabian Style

Gulati, Vishal; Wallace, Ron. 2012. "Rafts, Nanoparticles and Neural Disease." Nanomaterials 2, no. 3: 217-250.

Nanomaterials EISSN 2079-4991 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert